Search

Toby GD Capstick,1 Nicholas S Hopkinson2 1Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK; 2National Heart and Lung Institute, Imperial College, London, UKCorrespondence: Nicholas S HopkinsonNational Heart and Lung Institute, Imperial College, London, Royal Brompton Hospital Campus, Fulham Road, London, SW3 6NP, UKEmail n.hopkinson@ic.ac.UkAbstract: The takeover of Vectura, a healthcare company specialising in inhaled medication, by Philip Morris International raises serious ethical concerns. The European Respiratory Society notes that “health professionals will avoid prescribing drugs from any company that enriches the tobacco industry due to the ethical implications”. People with chronic obstructive pulmonary disease (COPD) and asthma will also be reluctant to use medications which profit a company that is estimated to kill at least one million people every year. We discuss the practicalities involved in switching people with lung disease to inhaled medications that are not tobacco industry linked. Potential alternative inhaled medications are set out, which are likely to be equally effective for most patients. A consideration of beneficence, non-maleficence, autonomy, and distributive justice demonstrates strong ethical reasons to support switching away from the prescription of tobacco industry linked products.Keywords: ethics, corporate social responsibility, public health

Capstick TGD, Hopkinson NS. Int J Chron Obstruct Pulmon Dis. 2021;16:2917–2923. The authors have advised there are minor errors in Table 2 on pages 2920–2921. The correct Table 2 is shown in Download Article. The authors apologize for these errors and advise they do not affect the results of the paper. Read the original article